Durvalumab bulk supplier for pharma manufacturers

Durvalumab 120 mg/4 mL, 500 mg/10 mL Suppliers & Bulk Manufacturers

Available Forms: Injection

Available Strengths: 120 mg/4 mL, 500 mg/10 mL

Reference Brands: Imfinzi® (US & EU)

Durvalumab (Imfinzi®) is a PD-L1 checkpoint inhibitor used for urothelial carcinoma and NSCLC treatment. Available as sterile intravenous infusion vials (120 mg/4 mL, 500 mg/10 mL), it complies with EU-GMP and USFDA standards. Offered for B2B supply, hospital tenders, and licensing in regulated markets.

Get Enquiry / Request Bulk Quote

Quick Response Guaranteed | Verified Suppliers

Product Description:

Durvalumab (Imfinzi®) is a PD-L1 immune checkpoint inhibitor indicated for urothelial carcinoma and non-small cell lung cancer. Provided as sterile intravenous infusion vials (120 mg/4 mL and 500 mg/10 mL), Durvalumab is manufactured under EU-GMP and USFDA standards. Available for B2B supply, contract manufacturing, and licensing, it supports hospital tenders and oncology distributors with full regulatory documentation. This monoclonal antibody enhances anti-tumor immunity by blocking PD-L1, making it a critical drug in immuno-oncology portfolios across the US and European markets.

Durvalumab — third party manufacturing & bulk supply

Durvalumab 120 mg/4 mL, 500 mg/10 mL is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:

Wholesale / bulk supply Stock or scheduled supply from an existing manufacturer. The fastest route where the product is already registered in your market.

Third party manufacturing Manufactured to your specification and packed under your own brand and label — suits distributors and brand owners building a portfolio in their market.

Dossier licensing Where a CTD, EU-CTD or ACTD dossier exists it can often be licensed for filing in your name, compressing market entry from years to months.

Indicative minimum order quantity

Durvalumab is supplied as Injection — an injectable dosage form, so the indicative MOQ is 50,000 units. Actual MOQ is confirmed by the allocated manufacturer against your pack presentation and destination market. See full supply terms for dossier formats, market availability and shelf life.

Manufacturers of Durvalumab listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding.

Request a quote for Durvalumab →

Back to Listing

Frequently Asked Questions

Durvalumab is used to treat certain types of cancer, including unresectable stage III non-small cell lung cancer (NSCLC) after chemoradiation therapy and extensive-stage small cell lung cancer (ES-SCLC) in combination with chemotherapy. It is also indicated for advanced or metastatic urothelial carcinoma. Durvalumab works by helping the immune system detect and attack cancer cells more effectively.

Durvalumab is a fully human monoclonal antibody made using recombinant DNA technology. It specifically targets and blocks the programmed death-ligand 1 (PD-L1) protein on cancer cells, which allows T cells to recognize and destroy these cells. The active ingredient is Durvalumab, and inactive components include histidine, sucrose, polysorbate 80, and water for injection.

The trade name of Durvalumab is Imfinzi.

Durvalumab is developed and manufactured by AstraZeneca Pharmaceuticals LP, a leading global biopharmaceutical company headquartered in the United Kingdom.

The generic name of the product is Durvalumab.

The brand name of the product is Imfinzi.

Durvalumab (Imfinzi) is manufactured by AstraZeneca at facilities located in the United Kingdom and the United States, and it is also produced in other AstraZeneca manufacturing sites in Europe to meet global demand.